Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $187000.0.

  • Mirum Pharmaceuticals' Capital Expenditures rose 331.49% to $187000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $374000.0, marking a year-over-year decrease of 6156.22%. This contributed to the annual value of $993000.0 for FY2024, which is 81100.92% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Capital Expenditures stood at $187000.0 for Q3 2025, which was up 331.49% from $126000.0 recorded in Q2 2025.
  • Mirum Pharmaceuticals' 5-year Capital Expenditures high stood at $779000.0 for Q2 2024, and its period low was $3000.0 during Q1 2021.
  • Moreover, its 5-year median value for Capital Expenditures was $41000.0 (2023), whereas its average is $117200.0.
  • In the last 5 years, Mirum Pharmaceuticals' Capital Expenditures plummeted by 9693.88% in 2021 and then soared by 796666.67% in 2022.
  • Over the past 5 years, Mirum Pharmaceuticals' Capital Expenditures (Quarter) stood at $3000.0 in 2021, then surged by 7966.67% to $242000.0 in 2022, then plummeted by 71.9% to $68000.0 in 2023, then tumbled by 70.59% to $20000.0 in 2024, then skyrocketed by 835.0% to $187000.0 in 2025.
  • Its Capital Expenditures was $187000.0 in Q3 2025, compared to $126000.0 in Q2 2025 and $41000.0 in Q1 2025.